Table 3

Dichotomous efficacy outcomes at 2 years for all patients and for subgroups

Baseline NNurse led n=114Usual care n=172Risk ratio (95% CI)
2 years, nNurse led n=112Usual care n=144
Primary outcome: p-urate<0.36 mmol/L—all patients
 Baseline n (%)0 (0%)12 (7%)0.00 (0.00 to 0.54)
 2 years n (%)92 (82%)63 (44%)1.88 (1.35 to 2.63)
p-urate<0.36 mmol/L for patients age >70 years
 Baseline n (%)0 (0%)4 (5%)0.00 (0.00 to 2.41)
 2 years n (%)41 (84%)28 (45%)1.85 (1.12 to 3.11)
p-urate<0.36 mmol/L for patients eGFR<60 mL/min/1.73 m2
 Baseline n (%)0 (0%)0 (0%)0.00 (0 to 0.09)
 2 years n (%)31 (84%)29 (52%)1.62 (0.94 to 2.78)
p-urate<0.36 mmol/L for patients p-urat>0.50 mmol/L at baseline
 Baseline (p-urate>0.50 mmol/ baseline)83 (73%)104 (60%)1.20 (0.89 to 1.62)
 2 years n (%)68 (84%)37 (44%)1.91 (1.26 to 2.93)
p-urate<0.36 mmol/L for female patients
 Baseline n (%)0 (0%)4 (10%)0.00 (0.00 to 3.98)
 2 years n (%)15 (94%)14 (48%)1.94 (0.87 to 4.34)
p-urate<0.36 mmol/L by use of diuretics
 Baseline n (%)0 (0%)2 (2%)0.00 (0.00 to 11.4)
 2 years n (%)33 (89%)33 (52%)1.70 (1.02 to 2.85)
p-urate<0.30 mmol/L for patients with tophi
 Baseline n (%)0 (0%)1 (2%)0.00 (0.00 to 41.4)
 2 years n (%)29 (60%)13 (33%)1.86 (0.94 to 3.90)
Ongoing urate-lowering therapy
 Baseline n (%)22 (19%)31 (18%)1.07 (0.59 to 1.91)
 2 years n (%)110 (98%)105 (73%)1.35 (1.02 to 1.78)
  • At 2 years assessment, we have excluded all 30 patients who died the first year. CI indicates 95% CI for incidence rate ratio.

  • eGFR, estimated glomerular filtration rate.